Study 32 – Achieving Cannabis Cessation-Evaluation of N-Acetylcysteine (ACCENT); CTN-0053

Investigator:  Kevin M. Gray, M.D. (Medical University of South Carolina) Release Date:  TBA Abstract:  This study is a 12-week, double-blind, randomized, placebo controlled trial of N-acetylcysteine (NAC) 1200mg twice daily, added to contingency management (CM), for the treatment of cannabis use among treatment-seeking cannabis-dependent adults (18-60).  Approximately 300 participants will be randomized into this 6-site … Continue reading Study 32 – Achieving Cannabis Cessation-Evaluation of N-Acetylcysteine (ACCENT); CTN-0053